Stock report · Delisted · Nasdaq
Aileron Therapeutics Inc (ALRN)
2.11USD Delisted Final close · Jan 10, 2025
ALRN no longer trades. Aileron Therapeutics was delisted from the Nasdaq in January 2025.
All prices on this page are historical. The last trade was on January 10, 2025, at $2.11.
ALRN stock price history
Final trading statistics
- Final close
- $2.11
- Final trading day
- Jan 10, 2025
- Market cap at delisting
- $45.72M
- Shares outstanding
- 21.67M
- Final 52-week range
- $1.61 – $7.42
- Avg. volume (final 3 mo.)
- 100,202
- All-time high
- $298.20 · Oct 2017
- All-time low
- $1.15 · Nov 2023
- Return since IPO
- -99.0%
- Beta
- 2.34
- Book value / share
- $1.41
- Price / book
- 1.50
About Aileron Therapeutics Inc
Aileron Therapeutics, Inc. was a U.S. biopharmaceutical company working on medicines for rare lung and fibrosis conditions with unmet needs. Its lead candidate, LTI-03, was a peptide in a Phase 1b trial for idiopathic pulmonary fibrosis (IPF).
A second candidate, LTI-01, was a proenzyme that had finished Phase 1b and Phase 2a trials for loculated pleural effusion. Earlier-stage work targeted cystic fibrosis, along with a peptide program aimed at the caveolin-1 protein for systemic fibrosis.
Incorporated in 2001 and based in Austin, Texas, the company was known as Renegade Therapeutics, Inc. until February 2007. It was delisted from the Nasdaq in January 2025, with a final trade on January 10, 2025 at $2.11.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Austin, TX
- Employees
- 15
- IPO date
- June 29, 2017
- Delisted
- January 10, 2025
- SEC CIK
- 1420565
Aileron Therapeutics financials before the delisting
The last 5 fiscal years Aileron Therapeutics reported as a public company, fiscal year ending December.
ALRN revenue and net income
ALRN earnings per share
ALRN annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | −$15.7M | −$3.38 |
| FY2022 | $0.00 | −$27.0M | −$6.02 |
| FY2021 | $0.00 | −$25.8M | −$5.80 |
| FY2020 | $0.00 | −$21.8M | −$12.60 |
| FY2019 | $0.00 | −$28.8M | −$25.80 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Aileron Therapeutics stock FAQ
What happened to Aileron Therapeutics stock?
Aileron Therapeutics was delisted from the Nasdaq in January 2025. The final close was $2.11 on January 10, 2025.
Can I still buy ALRN stock?
No. ALRN is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on January 10, 2025.
What was the last price of ALRN?
ALRN last closed at $2.11 on January 10, 2025, which valued the company at about $45.72M.
How did Aileron Therapeutics do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Aileron Therapeutics reported revenue of $0.00 and net income of −$15.7M.
When did Aileron Therapeutics go public?
Aileron Therapeutics shares started trading on June 29, 2017.
ALRN no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.